Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know
Organon (OGN) closed at $16.26 in the latest trading session, marking a +1.82% move from the prior day.
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing
Organon (OGN) closed the most recent trading day at $15.88, moving +0.89% from the previous trading session.
Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield
Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future growth, but uncertainties and competition pose significant risks to revenue projections. Organon's high debt and interest payments are significant concerns, despite low P/S and P/E ratios suggesting undervaluation, and a strong dividend yield.
Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript)
Organon & Co. (NYSE:OGN ) JPMorgan Annual Healthcare Conference Call January 13, 2025 6:45 PM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be hosting this fireside chat with the Organon management team.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon (OGN) Ascends While Market Falls: Some Facts to Note
Organon (OGN) closed at $15.06 in the latest trading session, marking a +0.74% move from the prior day.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon price target raised to $20 from $19 at Goldman Sachs
Goldman Sachs raised the firm's price target on Organon to $20 from $19 and keeps a Neutral rating on the shares. The firm cites the company's announced FDA approval of VTAMA for the topical treatment of atopic dermatitis, or AD, in adults and pediatric patients 2 years of age and older. VTAMA's AD approval addresses multiple unmet needs in the atopic dermatitis market previously demonstrated by their Phase 3 results, though the firm expects successful launch will require a heightened level of investment in sales/marketing support given the primary care dimensions of the AD market, the analyst tells investors in a research note.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon: 7% Yield, 4x P/E, Big Upside Potential
Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has shown steady performance with growth in adjusted EBITDA and free cash flow. The acquisition of Dermavant and its promising treatment VTAMA for psoriasis and atopic dermatitis could be transformative, expanding OGN's reach into high-demand areas.
